3-(3,4-Dichlorophenyl)-3-butenol t-butyldimethylsilyl ether | 191673-30-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3,4-Dichlorophenyl)-3-butenol t-butyldimethylsilyl ether
• 英文别名: tert-butyl-[3-(3,4-dichlorophenyl)but-3-enoxy]-dimethylsilane
• CAS: 191673-30-0
• 化学式: C₁₆H₂₄Cl₂OSi
• 分子量: 331.357
• InChiKey: SURNLUQUBZMTRV-UHFFFAOYSA-N

物化性质

• 沸点：
  368.1±42.0 °C(Predicted)
• 密度：
  1.045±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.42
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3,4-Dichlorophenyl)-3-butenol t-butyldimethylsilyl ether 在 吡啶 、 盐酸 、 水 、 lithium perchlorate 、 氢化奎尼定 1,4-(2,3-二氮杂萘)二醚 、 三乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 甲苯 、 乙腈 、 叔丁醇 为溶剂， 生成 (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethanol
  参考文献：
  名称：

  速激肽受体拮抗剂联合：新型吗啉类似物的合成与立体化学结构-活性关系。

  摘要：

  我们在此报告了关于NK1，NK2和NK3速激肽受体结合亲和力的新型吗啉类似物12和13的合成和立体化学结构-活性关系。绝对构型控制了对更有效的结合亲和力的基本要求。（S，R）-12和（S，R）-13对NK1，NK2和NK3受体表现出高结合亲和力。

  DOI：

  10.1016/s0960-894x(00)00324-3
• 作为产物：
  描述：

  3,4-二氯溴苯 在 4-二甲氨基吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 硫酸 、 碘 、 magnesium 、 三乙胺 、 zinc(II) chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 3-(3,4-Dichlorophenyl)-3-butenol t-butyldimethylsilyl ether
  参考文献：
  名称：

  An efficient synthesis of enantiomerically pure 2-[(2R)-arylmorpholin-2-yl]ethanols, key intermediates of tachykinin receptor antagonist

  摘要：

  We report herein an efficient and practical synthetic method for the preparation of enantiomerically pure 2[(2R)-arylmorpholin-2-yl]ethanols 1a-d, key intermediates of tachykinin receptor antagonist. Sharpless catalytic asymmetric dihydroxylation of 4a-d was employed to introduce the required absolute stereochemistry, and cyclization of 7a-d was accomplished by the Mitsunobu reaction. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(98)00336-x

文献信息

• Method for treating an inflammatory disease
  申请人：Sankyo Company, Limited

  公开号：US06448247B1

  公开（公告）日：2002-09-10

  Compounds of the formula and quaternary ammonium ions thereof, wherein R1 and R2 are the same or different and are carbocyclic aryl or aromatic heterocyclic; A is methylene, carbonyl or sulfonyl; B is a single bond, C1-C4 alkylene or C2-C4 alkenylene; D is oxygen or sulfur; E is C2-C6 alkylene, C1-C6 haloalkylene, C3-C6 cycloalkane-1,1-diyl or C3-C6-cycloalkane-1,1-diylmethyl; G is C1-C4 alkylene or C2-C4 alkenylene; and L is —NR3 or —C(R4)(R5), wherein R3 is a carbocyclic aryl or an aromatic heterocyclic; R4 is hydrogen, carbocyclic aryl or aromatic heterocyclic; R5 is —COR6, C1-C6 alkyl, C1-C6 alkoxy, amino, or acylamino, wherein R6 is C1-C6 alkyl or C1-C6 alkoxy, or R4 and R5 together with the carbon atom to which they are attached represent a C5-C10 cycloalkyl or a C5-C10 heterocyclic. The compounds have tachykinin receptor antagonist activity and exhibit an activity against both the NK1 and NK2 receptors.

  该分子式的化合物及其季铵盐，其中R1和R2相同或不同，为碳环芳基或芳香族杂环；A为亚甲基，羰基或磺酰基；B为单键，C1-C4烷基或C2-C4烯基；D为氧或硫；E为C2-C6烷基，C1-C6卤代烷基，C3-C6环烷-1,1-二基或C3-C6-环烷-1,1-二基甲基；G为C1-C4烷基或C2-C4烯基；L为—NR3或—C（R4）（R5），其中R3为碳环芳基或芳香族杂环；R4为氢，碳环芳基或芳香族杂环；R5为—COR6，C1-C6烷基，C1-C6烷氧基，氨基或酰胺基，其中R6为C1-C6烷基或C1-C6烷氧基，或R4和R5与它们连接的碳原子一起代表C5-C10环烷基或C5-C10杂环。这些化合物具有缓激肽受体拮抗活性，并对NK1和NK2受体均表现出活性。
• Heterocyclic compounds having tachykinin receptor antagonist activity
  申请人：Sankyo Company, Limited

  公开号：US06159967A1

  公开（公告）日：2000-12-12

  Compounds of the formula and quaternary ammonium ions thereof, wherein R.sup.1 and R.sup.2 are the same or different and are carbocyclic aryl or aromatic heterocyclic; A is methylene, carbonyl or sulfonyl; B is a single bond, C.sub.1 -C.sub.4 alkylene or C.sub.2 -C.sub.4, alkenylene; D is oxygen; E is C.sub.2 alkylene; G is C.sub.1 -C.sub.4 alkylene or C.sub.2 -C.sub.4 alkenylene; and L is --C(R.sup.4)(R.sup.5), wherein R.sup.4 and R.sup.5 together with the carbon atom to which they are attached represent a C.sub.5 -C.sub.10 cycloalkyl or a C.sub.5 -C.sub.10 heterocyclic. Especially preferred are compounds wherein L represents ##STR1## wherein J is a C.sub.1 -C.sub.6 alkylene; Ar is a ring carbocyclic or aromatic heterocyclic and S*.fwdarw.O is a sulfoxide in which the sulfur atom is in the 5-configuration. The compounds have tachykinin receptor antagonist activity and exhibit an activity against both the NK.sub.1 and NK.sub.2 receptors.

  该化合物的配方及其季铵离子，其中R.sup.1和R.sup.2相同或不同，是碳环芳基或芳香杂环；A是亚甲基，羰基或磺酰基；B是单键，C.sub.1-C.sub.4烷基或C.sub.2-C.sub.4烯基；D是氧；E是C.sub.2烷基；G是C.sub.1-C.sub.4烷基或C.sub.2-C.sub.4烯基；L是--C(R.sup.4)(R.sup.5)，其中R.sup.4和R.sup.5与它们附着的碳原子一起表示C.sub.5-C.sub.10环烷基或C.sub.5-C.sub.10杂环。特别喜欢的化合物是其中L表示##STR1##其中J是C.sub.1-C.sub.6烷基；Ar是环状碳环或芳香杂环，S*.fwdarw.O是一种亚砜，其中硫原子处于5位构型。这些化合物具有速激肽受体拮抗剂活性，并对NK.sub.1和NK.sub.2受体均有活性。
• Combined NK1 and NK2 tachykinin receptor antagonists: Synthesis and structure-activity relationships of novel oxazolidine analogues
  作者：Takahide Nishi、Tetsuya Fukazawa、Koki Ishibashi、Katsuyoshi Nakajima、Yuki Sugioka、Yukiko Iio、Hitoshi Kurata、Kazuhiro Itoh、Osamu Mukaiyama、Yumiko Satoh、Takeshi Yamaguchi

  DOI：10.1016/s0960-894x(99)00093-1

  日期：1999.3

  We report herein the synthesis and structure-activity relationships of a series of novel oxazolidine analogues with regards to NK1 and NK2 tachykinin receptor binding affinity. Among this series of oxazolidine analogues, some compounds exhibited excellent high binding affinities for both NK1 and NK2 receptors. In addition, we describe the inhibitory effect in vivo on SP-induced airway vascular hyperpermeability and NKA-induced bronchoconstriction in guinea pigs. (C) 1999 Elsevier Science Ltd. All rights reserved.
• An efficient synthesis of enantiomerically pure 2-[(2R)-arylmorpholin-2-yl]ethanols, key intermediates of tachykinin receptor antagonist
  作者：Takahide Nishi、Koki Ishibashi、Katsuyoshi Nakajima、Yukiko Iio、Tetsuya Fukazawa

  DOI：10.1016/s0957-4166(98)00336-x

  日期：1998.9

  We report herein an efficient and practical synthetic method for the preparation of enantiomerically pure 2[(2R)-arylmorpholin-2-yl]ethanols 1a-d, key intermediates of tachykinin receptor antagonist. Sharpless catalytic asymmetric dihydroxylation of 4a-d was employed to introduce the required absolute stereochemistry, and cyclization of 7a-d was accomplished by the Mitsunobu reaction. (C) 1998 Elsevier Science Ltd. All rights reserved.
• Combined tachykinin receptor antagonist: synthesis and stereochemical structure–activity relationships of novel morpholine analogues
  作者：Takahide Nishi、Koki Ishibashi、Toshiyasu Takemoto、Katsuyoshi Nakajima、Tetsuya Fukazawa、Yukiko Iio、Kazuhiro Itoh、Osamu Mukaiyama、Takeshi Yamaguchi

  DOI：10.1016/s0960-894x(00)00324-3

  日期：2000.8

  We report herein the synthesis and stereochemical structure-activity relationships of novel morpholine analogues 12 and 13 with regards to NK1, NK2 and NK3 tachykinin receptor binding affinity. An essential requirement for more potent binding affinities was controlled by absolute configuration. (S,R)-12 and (S,R)-13 exhibited high binding affinities for NK1, NK2 and NK3 receptors.

  我们在此报告了关于NK1，NK2和NK3速激肽受体结合亲和力的新型吗啉类似物12和13的合成和立体化学结构-活性关系。绝对构型控制了对更有效的结合亲和力的基本要求。（S，R）-12和（S，R）-13对NK1，NK2和NK3受体表现出高结合亲和力。